Raymond James Financial
SONM icon

Raymond James Financial’s DNA X Inc SONM Stock Holding History

Raymond James Financial’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$40 – 6508
2025
Q2 		$40 Buy
+2
New +$49 ﹤0.01% 6899

Other funds holding SONM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWM
Dogwood Wealth Management Lenexa, Kansas $253M AUM 19.41% 1-Year Est. Return

Raymond James Financial's SONM Position: Q3 2025 in Review

Raymond James Financial sold out of DNA X Inc (SONM) in Q3 2025, closing a stake of 2 shares — an estimated $40 sold.

Raymond James Financial first reported a position in SONM in Q2 2025 and held it in 1 quarter. The position peaked at $40 in Q2 2025. 12 funds tracked by Wall St. Rank hold SONM as of Q3 2025.

  • Raymond James Financial reported no remaining DNA X Inc position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2 DNA X Inc shares in Q3 2025, an estimated $40.
  • Raymond James Financial first reported a position in DNA X Inc in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's DNA X Inc position peaked at $40 in Q2 2025.
  • 12 funds tracked by Wall St. Rank held DNA X Inc as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.